Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing Atezolizumab and Sipuleucel-T in mCRPC
NCT03024216Phase 1Completed
- Sponsor
- University of Hawaiʻi
- Start
- Feb 2017
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by University of Hawaiʻi. Primary endpoints: Assessment of Adverse Events by CTCAE v4.0 at 12 months and Clinically significant changes in vital signs and clinical laboratory results at 12 months. Started Feb 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03024216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03024216.